Cantor Fitzgerald analyst Kristen Kluska believes the jump in Rigel Pharmaceuticals’ (RIGL) shares on Monday is due to a preliminary research report citing fostamatinib as a potential candidate for treating acute lung injury related to COVID-19. Â The analyst… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3124594/-Rigel-surges-as-study-cites-fostamatinib-as-potential-candidate-to-treat-COVID)